Az egyetemek szerepe a progresszív betegellátás rendszerében.

Translated title of the contribution: The role of medical schools in progressive health care

I. Boncz, Andor Sebestyén

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

AIM: To analyse the predicted and observed role of medical schools in the progressive health care. DATA AND METHODS: The data derives from the financial database of the National Health Insurance Fund (NHIF) and covering the period 1998-2001. In this study the authors calculated the market share of the medical schools within the financing of the NHIF in the field of out- and in-patient care, renal dialysis, CT/MRI examinations, task financed services under special rules and fee for progressive (tertier level) care. The authors performed a detailed analysis concerning the Diagnosis Related Groups (DRG) of active inpatient care, where the market share of medical schools was calculated within the TOP-15 DRGs with highest and lowest point value, and within the TOP-15 most common and most infrequent DRGs. RESULTS: The market share of medical schools increased from 13.7% (1998) to 15.0% (2001). The increase was significant in the active and chronic in-patient care and in renal dialysis. The market share of medical schools from progressive fee decreased from 32.3% (1998) to 26.5% (2001). Within the active in-patient care the medical schools provide health care for 37.7% of the most difficult cases with highest DRG value and for 30.1% of the patients with rare diseases. The market share of the medical schools is much lower in cases with lowest DRG value (10.2%) and in most common cases (9.8%). CONCLUSION: The medical schools fulfilled their expected role in the progressive (tertier) care, answering the public and professional expectations.

Original languageHungarian
Pages (from-to)523-528
Number of pages6
JournalOrvosi Hetilap
Volume144
Issue number11
Publication statusPublished - Mar 16 2003

Fingerprint

Medical Schools
Diagnosis-Related Groups
Delivery of Health Care
Patient Care
Fees and Charges
National Health Programs
Renal Dialysis
School Health Services
Rare Diseases
Inpatients
Outpatients
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az egyetemek szerepe a progresszív betegellátás rendszerében. / Boncz, I.; Sebestyén, Andor.

In: Orvosi Hetilap, Vol. 144, No. 11, 16.03.2003, p. 523-528.

Research output: Contribution to journalArticle

Boncz, I & Sebestyén, A 2003, 'Az egyetemek szerepe a progresszív betegellátás rendszerében.', Orvosi Hetilap, vol. 144, no. 11, pp. 523-528.
Boncz, I. ; Sebestyén, Andor. / Az egyetemek szerepe a progresszív betegellátás rendszerében. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 11. pp. 523-528.
@article{d951898d778d4d8695ee716860deb1d9,
title = "Az egyetemek szerepe a progressz{\'i}v betegell{\'a}t{\'a}s rendszer{\'e}ben.",
abstract = "AIM: To analyse the predicted and observed role of medical schools in the progressive health care. DATA AND METHODS: The data derives from the financial database of the National Health Insurance Fund (NHIF) and covering the period 1998-2001. In this study the authors calculated the market share of the medical schools within the financing of the NHIF in the field of out- and in-patient care, renal dialysis, CT/MRI examinations, task financed services under special rules and fee for progressive (tertier level) care. The authors performed a detailed analysis concerning the Diagnosis Related Groups (DRG) of active inpatient care, where the market share of medical schools was calculated within the TOP-15 DRGs with highest and lowest point value, and within the TOP-15 most common and most infrequent DRGs. RESULTS: The market share of medical schools increased from 13.7{\%} (1998) to 15.0{\%} (2001). The increase was significant in the active and chronic in-patient care and in renal dialysis. The market share of medical schools from progressive fee decreased from 32.3{\%} (1998) to 26.5{\%} (2001). Within the active in-patient care the medical schools provide health care for 37.7{\%} of the most difficult cases with highest DRG value and for 30.1{\%} of the patients with rare diseases. The market share of the medical schools is much lower in cases with lowest DRG value (10.2{\%}) and in most common cases (9.8{\%}). CONCLUSION: The medical schools fulfilled their expected role in the progressive (tertier) care, answering the public and professional expectations.",
author = "I. Boncz and Andor Sebesty{\'e}n",
year = "2003",
month = "3",
day = "16",
language = "Hungarian",
volume = "144",
pages = "523--528",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "11",

}

TY - JOUR

T1 - Az egyetemek szerepe a progresszív betegellátás rendszerében.

AU - Boncz, I.

AU - Sebestyén, Andor

PY - 2003/3/16

Y1 - 2003/3/16

N2 - AIM: To analyse the predicted and observed role of medical schools in the progressive health care. DATA AND METHODS: The data derives from the financial database of the National Health Insurance Fund (NHIF) and covering the period 1998-2001. In this study the authors calculated the market share of the medical schools within the financing of the NHIF in the field of out- and in-patient care, renal dialysis, CT/MRI examinations, task financed services under special rules and fee for progressive (tertier level) care. The authors performed a detailed analysis concerning the Diagnosis Related Groups (DRG) of active inpatient care, where the market share of medical schools was calculated within the TOP-15 DRGs with highest and lowest point value, and within the TOP-15 most common and most infrequent DRGs. RESULTS: The market share of medical schools increased from 13.7% (1998) to 15.0% (2001). The increase was significant in the active and chronic in-patient care and in renal dialysis. The market share of medical schools from progressive fee decreased from 32.3% (1998) to 26.5% (2001). Within the active in-patient care the medical schools provide health care for 37.7% of the most difficult cases with highest DRG value and for 30.1% of the patients with rare diseases. The market share of the medical schools is much lower in cases with lowest DRG value (10.2%) and in most common cases (9.8%). CONCLUSION: The medical schools fulfilled their expected role in the progressive (tertier) care, answering the public and professional expectations.

AB - AIM: To analyse the predicted and observed role of medical schools in the progressive health care. DATA AND METHODS: The data derives from the financial database of the National Health Insurance Fund (NHIF) and covering the period 1998-2001. In this study the authors calculated the market share of the medical schools within the financing of the NHIF in the field of out- and in-patient care, renal dialysis, CT/MRI examinations, task financed services under special rules and fee for progressive (tertier level) care. The authors performed a detailed analysis concerning the Diagnosis Related Groups (DRG) of active inpatient care, where the market share of medical schools was calculated within the TOP-15 DRGs with highest and lowest point value, and within the TOP-15 most common and most infrequent DRGs. RESULTS: The market share of medical schools increased from 13.7% (1998) to 15.0% (2001). The increase was significant in the active and chronic in-patient care and in renal dialysis. The market share of medical schools from progressive fee decreased from 32.3% (1998) to 26.5% (2001). Within the active in-patient care the medical schools provide health care for 37.7% of the most difficult cases with highest DRG value and for 30.1% of the patients with rare diseases. The market share of the medical schools is much lower in cases with lowest DRG value (10.2%) and in most common cases (9.8%). CONCLUSION: The medical schools fulfilled their expected role in the progressive (tertier) care, answering the public and professional expectations.

UR - http://www.scopus.com/inward/record.url?scp=0038043326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038043326&partnerID=8YFLogxK

M3 - Article

C2 - 12731339

AN - SCOPUS:0038043326

VL - 144

SP - 523

EP - 528

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 11

ER -